-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reviewing Bone Biologics (OTC:BBLG) & Sientra (NASDAQ:SIEN)
Reviewing Bone Biologics (OTC:BBLG) & Sientra (NASDAQ:SIEN)
Bone Biologics (OTC:BBLG – Get Rating) and Sientra (NASDAQ:SIEN – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Bone Biologics and Sientra's net margins, return on equity and return on assets.
Get Bone Biologics alerts:Net Margins | Return on Equity | Return on Assets | |
Bone Biologics | N/A | 7,587.33% | 7,258.20% |
Sientra | -76.47% | -381.27% | -36.56% |
Insider & Institutional Ownership
0.5% of Bone Biologics shares are owned by institutional investors. Comparatively, 68.4% of Sientra shares are owned by institutional investors. 1.3% of Sientra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Bone Biologics and Sientra's revenue, earnings per share and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
Sientra | $80.68 million | 0.31 | -$62.48 million | ($1.09) | -0.23 |
Bone Biologics has higher earnings, but lower revenue than Sientra.
Analyst Recommendations
This is a summary of current ratings and target prices for Bone Biologics and Sientra, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
Sientra | 0 | 1 | 6 | 0 | 2.86 |
Bone Biologics currently has a consensus target price of $2.25, indicating a potential upside of 837.50%. Sientra has a consensus target price of $5.19, indicating a potential upside of 2,010.59%. Given Sientra's higher probable upside, analysts clearly believe Sientra is more favorable than Bone Biologics.
Risk and Volatility
Bone Biologics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Sientra has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Summary
Sientra beats Bone Biologics on 6 of the 11 factors compared between the two stocks.
About Bone Biologics
(Get Rating)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
About Sientra
(Get Rating)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
Bone Biologics (OTC:BBLG – Get Rating) and Sientra (NASDAQ:SIEN – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.
骨生物(場外交易:BBLG-GET評級)和西恩特拉(納斯達克:SEN-GET評級)都是小盤醫療公司,但哪一家更好?我們將根據這兩家公司的盈利能力、估值、風險、收益、股息、分析師建議和機構所有權的強項對其進行比較。
Profitability
盈利能力
This table compares Bone Biologics and Sientra's net margins, return on equity and return on assets.
該表比較了骨生物和西恩特拉的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Bone Biologics | N/A | 7,587.33% | 7,258.20% |
Sientra | -76.47% | -381.27% | -36.56% |
淨利潤率 | 股本回報率 | 資產回報率 | |
骨生物製品 | 不適用 | 7,587.33% | 7,258.20% |
西恩特拉 | -76.47% | -381.27% | -36.56% |
Insider & Institutional Ownership
內部人與機構所有權
0.5% of Bone Biologics shares are owned by institutional investors. Comparatively, 68.4% of Sientra shares are owned by institutional investors. 1.3% of Sientra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
骨生物公司0.5%的股份由機構投資者持有。相比之下,Sientra 68.4%的股份由機構投資者持有。Sientra 1.3%的股份由內部人士持有。強大的機構持股表明,捐贈基金、大型基金管理公司和對衝基金相信,一隻股票有望實現長期增長。
Earnings & Valuation
收益與估值
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
Sientra | $80.68 million | 0.31 | -$62.48 million | ($1.09) | -0.23 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
骨生物製品 | 不適用 | 不適用 | -161萬美元 | 不適用 | 不適用 |
西恩特拉 | 8,068萬美元 | 0.31 | -6,248萬元 | ($1.09) | -0.23 |
Bone Biologics has higher earnings, but lower revenue than Sientra.
Bbone Biologics的收益比Sientra高,但收入比Sientra低。
Analyst Recommendations
分析師建議
This is a summary of current ratings and target prices for Bone Biologics and Sientra, as reported by MarketBeat.
這是MarketBeat報道的骨生物製品和Sientra的當前評級和目標價格的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
Sientra | 0 | 1 | 6 | 0 | 2.86 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
骨生物製品 | 0 | 0 | 1 | 0 | 3.00 |
西恩特拉 | 0 | 1 | 6 | 0 | 2.86 |
Bone Biologics currently has a consensus target price of $2.25, indicating a potential upside of 837.50%. Sientra has a consensus target price of $5.19, indicating a potential upside of 2,010.59%. Given Sientra's higher probable upside, analysts clearly believe Sientra is more favorable than Bone Biologics.
Bbone Biologics目前的共識目標價為2.25美元,表明潛在上行空間為837.50%。Sientra的共識目標價為5.19美元,表明潛在漲幅為2,010.59%。考慮到Sientra更有可能的上行空間,分析師們顯然認為Sientra比骨生物製藥更有利。
Risk and Volatility
風險和波動性
Bone Biologics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Sientra has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Bone Biologics的貝塔係數為0.11,這表明其股價的波動性比標準普爾500指數低89%。相比之下,Sientra的貝塔係數為1.51,這表明其股價的波動性比標準普爾500指數高出51%。
Summary
摘要
Sientra beats Bone Biologics on 6 of the 11 factors compared between the two stocks.
在兩隻股票比較的11個因素中,Sientra有6個擊敗了bone Biologics。
About Bone Biologics
關於骨生物製品
(Get Rating)
(獲取評級)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
骨生物公司是一家醫療設備公司,專注於使用重組人蛋白在脊柱融合中進行骨再生。該公司的Nell-1/DBX是一種組合產品,是一種骨刺激重組蛋白,提供對骨再生的靶向特異性控制。該公司正在開發Nell-1/DBX融合器,用於L4-S1一級退行性腰椎間盤疾病骨性成熟患者的脊柱融合手術。該公司的平臺技術在脊柱、整形外科、普通整形外科、整形外科、神經外科、介入放射學和運動醫學等外科專業中具有增強的應用效果。它與加州大學洛杉磯分校技術開發集團簽署了一項許可協議,開發和商業化用於脊柱融合應用的Nell-1。該公司成立於2004年,總部設在馬薩諸塞州伯靈頓。
About Sientra
關於Sientra
(Get Rating)
(獲取評級)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Sientra,Inc.是一家醫學美學公司,在美國和國際上開發和銷售醫學美學產品。該公司提供用於隆胸和乳房再造手術的硅膠乳房植入物;乳房組織擴張器;以及Sientra圓形、Sientra TearDrop、allX2、Dermaspan、SoftSpan和BIOCORNEUM品牌的疤痕處理產品。該公司還提供身體塑形產品;面部和鼻部植入物;生理鹽水填充的尺碼。它為醫院、外科中心、整形外科醫生、皮膚科醫生和其他專科醫生提供服務。該公司前身為Juliet Medical,Inc.,並於2007年4月更名為Sientra,Inc.。Sientra,Inc.成立於2003年,總部設在加利福尼亞州聖巴巴拉。
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受骨生物製品日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收骨生物和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧